Evidence map›Paper›PMID 40260290›Full record

ArticleFrontiers in oncology2025

Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights.

Ashish Manne, Yonghua Bao, Ankur Sheel, Amir Sara, Upender Manne, Kannan Thanikachalam, Ashwini Esnakula, Timothy M Pawlik, Jordan M Cloyd, Susan Tsai and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ashish ManneDepartment of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.
Yonghua BaoClinical & Translational Science Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.
Ankur SheelDepartment of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.
Amir SaraDepartment of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.
Upender ManneDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States.
Kannan ThanikachalamDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Ashwini EsnakulaDepartment of Pathology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.
Timothy M PawlikDepartment of Surgery, Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.
Jordan M CloydDepartment of Surgery, Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.
Susan TsaiDepartment of Surgery, Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.
Anup KasiDivision of Medical Oncology, University of Kansas Cancer Center, Westwood, KS, United States.
Ravi Kumar PaluriDivision of Hematology-Oncology, Department of Internal Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, United States.
Deepak SherpallyDepartment of Internal Medicine, New York Medical College, Valhalla, NY, United States.
Sravan JeepalyamDepartment of Internal Medicine, Stormont Vail Health, Topeka, KS, United States.
Lianbo YuCenter of Biostatistics and Bioinformatics, The Ohio State University, Columbus, OH, United States.
Wancai YangClinical & Translational Science Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We investigated the association between serum MUC5AC (sMUC5AC) levels and patient outcomes in individuals who underwent resection for pancreatic ductal adenocarcinoma (PDA), including those treated with neoadjuvant therapy (NAT) and those who had upfront surgery (UpS) followed by adjuvant therapy. Methods: Serum samples from the Ohio State University biorepository collected from January 2010 to June 2021 were utilized. The human MUC5AC kit (NBP2-76703) was used to perform enzyme-linked immunoassays to measure sMUC5AC levels. Logistic regression, Cox regression models (univariate and multivariate), recurrence prediction, analysis of variance (ANOVA), t-tests, and Wilcoxon tests were used for statistical analysis. Results: In the NAT cohort (n = 23), elevated sMUC5AC levels were significantly ( Conclusion: This study provides compelling evidence for the clinical utility of sMUC5AC as a prognostic biomarker among patients with resected PDA. Future large-scale studies are needed to validate these findings and establish standard thresholds for sMUC5AC integration into clinical practice.

Indexed as

biomarkerFOLFIRINOXMUC5ACneoadjuvant therapypancreatic cancerpredictingprognostic markerserum MUC5AC

Identifiers

PMID40260290
PMCPMC12010103

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.